340B Drug Pricing Program Reform: California's Opportunity to Lead on Transparency and Accountability

The federal 340B Drug Pricing Program (搜索)搜索该药品, originally designed to help hospitals and clinics serving vulnerable populations, has undergone explosive growth over the past 15 years — yet oversight and transparency have failed to keep pace. With the program now reaching an estimated $170 billion in 2025, up from just $6.6 billion in 2010, calls for reform are intensifying, and California is emerging as a potential leader in the push for accountability.

Created by Congress in 1992, the 340B program was intended to allow hospitals and clinics that serve uninsured and low-income patients to purchase medicines at discounted prices, thereby stretching scarce resources and expanding access to care. That mission, proponents argue, remains both noble and necessary. However, the program's evolution has raised significant questions about whether its benefits are reaching the patients Congress intended to help.

A Program Outpacing Its Oversight

Under current rules, participating hospitals can purchase medicines at deep discounts while often receiving full reimbursement from insurers. Yet federal law generally does not require those discounts to be passed directly to patients, nor does it mandate comprehensive public reporting that demonstrates exactly how 340B revenues improve patient care.

"Programs designed to serve the public should also be accountable to the public," reform advocates contend, pointing to the disconnect between the program's scale and its transparency.

The stakes extend beyond healthcare access. At a time when China and other global competitors are investing aggressively to dominate biotechnology and advanced medical research, the United States cannot afford policies that reduce confidence in the innovation ecosystem or obscure whether public programs deliver the value Congress intended. Every dollar spent inefficiently within the healthcare system is a dollar unavailable for patient care, research, or future medical breakthroughs.

California's Unique Position

California is home to many of America's premier research universities, biotechnology companies, pharmaceutical innovators, venture capital firms, and academic medical centers. Together, these entities form an innovation ecosystem that develops next-generation cancer treatments, gene therapies, Alzheimer's medicines, and cures for rare diseases — a strategic national asset.

The state has built one of the world's most successful biomedical economies by encouraging innovation while demanding accountability. Strong intellectual property protections, world-class research institutions, venture investment, and patient-centered health policies have made California a global leader in medical innovation. Reform advocates argue that modernizing 340B to improve transparency follows that same tradition.

Preserving the Safety Net While Demanding Results

Reform proponents emphasize that the goal is not to eliminate the 340B program. Genuine safety-net providers — including community health centers, rural hospitals, and facilities serving large numbers of uninsured patients — depend on 340B. Congress should preserve those benefits while modernizing the program for today's healthcare marketplace.

Key reform elements include requiring clear public reporting on how 340B revenues improve patient care, ensuring discounts benefit the patients Congress intended to help, strengthening oversight, and providing policymakers with the data needed to evaluate whether the program is achieving its statutory purpose.

Greater transparency would allow policymakers to identify which providers use discount revenues to expand access to care and which are simply generating additional institutional revenue without measurable patient benefits. Responsible hospitals would have the opportunity to demonstrate their success, while policymakers could target reforms that preserve the safety net without rewarding inefficiency.

Broader Implications for U.S. Competitiveness

The implications extend to multiple stakeholders. Patients would gain confidence that programs created on their behalf are actually serving them. Employers and workers' unions would benefit from a more efficient healthcare system that helps reduce upward pressure on premiums. Taxpayers would receive greater accountability. Most importantly, America's life sciences sector would operate within a healthcare system that rewards value, promotes transparency, and supports continued investment in research and development.

"America's global competitiveness depends not only on inventing tomorrow's cures but also on maintaining public confidence in the systems that support medical innovation," the reform perspective holds. "Reforming 340B is an opportunity to do both."

California, which has often demonstrated what responsible leadership looks like on the national stage, could once again establish a model that other states — and eventually Congress — can follow by championing transparency, accountability, and patient-focused reform of the 340B program.